Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Olle Melander

Principal investigator

Default user image.

Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol


  • Jadwiga Nessler
  • Bohdan Nessler
  • Renata Golebiowska-Wiatrak
  • Ilona Palka
  • Andrzej Gackowski
  • Mariusz Kitlinski
  • Olle Melander
  • Artur Fedorowski

Summary, in English

Background: The role of inflammatory and hemodynamic stress biomarkers in heart failure (HF) patients treated de novo with beta-blockers has been poorly studied. Methods: A total of 86 patients (age 56 +/- 9 years, 81 men) with left ventricular ejection fraction (LVEF) < 40% and previously not treated with beta-blockers were initiated on carvedilol. At baseline and 12 months later we performed echocardiography, cardiopulmonary exercise testing, and determined serum levels of B-type natriuretic peptide (BNP), endothelin-1 (ET-1), C-reactive protein (CRP), interleukin-6, and tumor necrosis factor alpha (TNF-alpha). Patients were followed up over a total period of 9 +/- 3 years from baseline. Results: Increased baseline CRP and its on-treatment decrease were associated with improvement of LVEF (est. coefficient per one SD: 1.6; 95% CI: -0.05,3.28; p = 0.056, and -1.80; -3.43, -0.18; p = 0.030, respectively) and diminishing of LV end-systolic volume index [mL/m(2)] (-6.83; -11.32; -2.34; p = 0.003, and 5.85; 1.23; -10.46; p = 0.014, respectively). Higher baseline ET-1 and on-treatment increase in TNF-alpha predicted frequent admissions (>1) for cardiac complications (odds ratio per one SD: 1.98; 95% CI: 1.09-3.59; p = 0.025, and 2.07, 1.12-3.84, p = 0.021, respectively) whereas higher baseline BNP was asociated with increased mortality (hazard ratio per one SD: 2.09, 95% CI: 1.26-3.45; p = 0.004). Conclusions: Serum biomarkers may have different roles in prediction of clinical outcomes among HF patients treated de novo with carvedilol. (Cardiol J 2013; 20, 2: 144-151)


  • Cardiovascular Research - Hypertension
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year







Cardiology Journal





Document type

Journal article


Via Medica


  • Cardiac and Cardiovascular Systems


  • heart failure
  • beta-blocker
  • biological markers
  • natriuretic peptides
  • endothelin-1
  • C-reactive protein



Research group

  • Cardiovascular Research - Hypertension


  • ISSN: 1898-018X